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Abstract
Background: It has been documented all-trans retinoic acid (atRA) promotes the development of TGF-b-induced
CD4
+Foxp3
+ regulatory T cells (iTreg) that play a vital role in the prevention of autoimmune responses, however, molecular
mechanisms involved remain elusive. Our objective, therefore, was to determine how atRA promotes the differentiation of
iTregs.
Methodology/Principal Findings: Addition of atRA to naı ¨ve CD4
+CD25
2 cells stimulated with anti-CD3/CD28 antibodies in
the presence of TGF-b not only increased Foxp3
+ iTreg differentiation, but maintained Foxp3 expression through apoptosis
inhibition. atRA/TGF-b-treated CD4
+ cells developed complete anergy and displayed increased suppressive activity. Infusion
of atRA/TGF-b-treated CD4
+ cells resulted in the greater effects on suppressing symptoms and protecting the survival of
chronic GVHD mice with typical lupus-like syndromes than did CD4
+ cells treated with TGF-b alone. atRA did not
significantly affect the phosphorylation levels of Smad2/3 and still promoted iTreg differentiation in CD4
+ cells isolated from
Smad3 KO and Smad2 conditional KO mice. Conversely, atRA markedly increased ERK1/2 activation, and blockade of ERK1/2
signaling completely abolished the enhanced effects of atRA on Foxp3 expression. Moreover, atRA significantly increased
histone methylation and acetylation within the promoter and conserved non-coding DNA sequence (CNS) elements at the
Foxp3 gene locus and the recruitment of phosphor-RNA polymerase II, while DNA methylation in the CNS3 was not
significantly altered.
Conclusions/Significance: We have identified the cellular and molecular mechanism(s) by which atRA promotes the
development and maintenance of iTregs. These results will help to enhance the quantity and quality of development of
iTregs and may provide novel insights into clinical cell therapy for patients with autoimmune diseases and those needing
organ transplantation.
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Introduction
All-trans-retinoic acid (atRA), a Vitamin A derivative, has
profound effects on embryonal morphogenesis, vision, reproduc-
tion, cell differentiation, growth, and immune homeostasis [1].
Deficiency of vitamin A leads to exacerbation of experimental
colitis [2]. In the immune system, atRA plays important roles in
regulating the functions of many different cell types [3]. Vitamin A
and its derivatives are capable of ameliorating several models of
autoimmunity, including inflammatory bowel disease, rheumatoid
arthritis, type I diabetes, and experimental encephalomyelitis
[4–5]. In addition to the inhibitory effect of atRA on T effector cell
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24590differentiation and function, atRA has also been shown to be
capable of promoting murine CD4
+Foxp3
+ Tregs induced by
TGF-b from conventional CD4
+Foxp3
2 cells, either directly by
enhancing TGF-b-driven Smad3 signaling in naive cells and/or
indirectly by relieving the production of pro-inflammatory
cytokines from murine memory effector cells [6–8]. Such
approaches show great promise as these T cells have been shown
effective in combating several immune-mediated disorders [9].
CD4
+CD25
+ T regulatory (Treg) cells play a critical role in
establishing and maintaining self-tolerance. Therefore, enhancing
the number and/or function of Tregs represents a potential
treatment for patients with autoimmune disorders or those who
undergo transplant rejection. atRA can strongly increase TGF-b-
induced Foxp3 expression and Treg conversion in vitro [6]. Under
these conditions, atRA may enhance TGF-b signaling by
increasing the expression and phosphorylation of Smad3. On
the other hand, it has also been reported that expression of RAR
can be increased through TGF-b signaling [10]. Therefore, atRA
and TGF-b may cooperatively augment their mutual signaling to
further enhance Foxp3 expression. However, the exact roles of
atRA in these signaling pathways are less well understood.
We recently reported that while the Smad pathway plays a less
important role in the differentiation of Foxp3
+ iTregs induced by
TGF-b, ERK and JNK kinases which mainly use non-Smad
pathways, may play a more significant role in this process [11].
Herein, we further demonstrate that adding atRA to cultures
containing TGF-b not only increases Foxp3 expression and
maintenance, but also enhances the suppressive activities of these
Tregs in vitro and in vivo. Studies of the underlying mechanism
responsible for these observations indicate that atRA upregulates
ERK rather than Smad2/3 activation of the TGF-b down-stream
signaling pathway. Additionally, Foxp3 induced by a combination
of atRA and TGF-b displayed increased Foxp3 binding ability on
chromatin compared to that induced by TGF-b alone. We further
found that atRA enhances histone methylation and acetylation in
Foxp3 promoter and its conserved non-coding DNA sequence
elements (CNS2), rather than DNA CpG demethylation of CNS3
in the Foxp3 locus. Thus, atRA improves both the quantity and
quality of Foxp3
+ iTregs, findings which will be important in the
development of superior cell therapies to treat autoimmune
diseases and prevent organ transplantation rejection.
Results
atRA directly up-regulates Foxp3 and sustains its
expression by CD4
+ cells treated with TGF-b
In agreement with previous reports [6], addition of atRA to
cultures containing TGF-b significantly enhanced the proportions
of CD4
+CD25
+Foxp3
+ cells induced from naive CD4
+
CD25
2Foxp3
2 (or GFP
2 cells using WT or Foxp3 GFP knock-
in mice). This effect may reflect either direct Foxp3
+ cell induction
or a secondary effect through suppression of CD4
+Foxp3
2 cell
expansion [8]. In either case, total Foxp3 protein levels and
Foxp3
+ cell numbers increased significantly in CD4
+ cells treated
with the combination of atRA and TGF-b than those treated with
TGF-b alone, indicating that atRA has a direct effect on the
enhancement of iTreg differentiation, although it may also
simultaneously suppress CD4
+Foxp3
2 cell expansion (Figure
S1A–D).
We also examined other phenotypic features related to Treg
differentiation. As reported by others [12], addition of atRA to
TGF-b markedly increased the expression of CD103, CCR-9,
a4b7 by CD4
+ cells (Figure S1E), we also observed that addition
of atRA significantly decreased IL-2 production, increased
membrane bound TGF-b expression and slightly increased IL-
10 production (Figure S1E).
In addition to a direct effect of atRA on Foxp3
+ cell
differentiation, atRA also maintains Foxp3 expression in TGF-b-
primed CD4
+CD25
+ cells. As shown in Figure 1A, Foxp3
expression in CD4
+CD25
+ cells treated with TGF-b appeared on
day 1 and peaked on day 3–5. Foxp3 expression gradually
declined after 6 days in the culture and remained at lower levels on
day 10. Of note, the addition of atRA not only increased, but
sustained Foxp3 expression by TGF-b-primed CD4
+ cells. We
conducted further in vivo experiments to determine whether both
Treg cell subsets have different fates after cell transfer. iTregs were
generated as described above from C57BL/6 Thy1.1 mice and
adoptively transferred into syngeneic C57BL/6 Thy1.2 mice.
Spleen, blood and lymph node (LN) cells were stained for Foxp3
and Thy1.1 on day 10, 20 and 30 after cell transfer. Thy1.1
expression is used to distinguish the donor cells from recipient
cells. While total donor CD4TGF-b cells dramatically declined on
day 30, the Foxp3
+ cell subset from these cells significantly
decreased on day 20 and even more on day 30 after cell transfer in
LNs (Figure 1B-D), blood and spleen (not shown). In sharp
contrast, total donor CD4TGF-b+atRA cell numbers are sustained
during 10–30 days after cell transfer. Although the percentages of
Foxp3
+ population among CD4TGF-b+atRA cells was slightly lower
in day 20-30 than in day 0, the Foxp3
+ population was still
significantlyhigherindonorCD4TGF-b+atRAcellsthaninCD4TGF-b
cells in LNs (Figure 1B–C). This phenonemon was similarly
observed in peripheral blood and spleen, excluding the possibility
that the re-distribution of donor cells affects the frequency of Treg
cells in the different donor cell populations post injection. We
furtherobserved that the additionof atRA to TGF-b-treated culture
significantly decreases the proportion of Annexin-V
+GFP
+ (apo-
ptotic Foxp3
+) cells (Figure 1E) and up-regulates the expression of
Bcl-2 (an anti-apoptotic gene) (Figure 1F, left panel), suggesting
that atRA maintains Foxp3 expression through its effect on
protecting these cells from apoptosis. Although atRA induces
cancer cell apoptosis and contributes to cancer treatment [13], it
actually suppresses apoptosis in non-tumor human cells including
lymphocytes, eosinophils and neuronal cells [14]. We further
demonstrated that atRA/RAR rather than atRA/RXR signal
pathway is crucial for the upregulation of Bcl-2 expression since
additon of LE540 (an RAR antagonist) rather than of SR11237 (an
RXR antagonist) abolished the effect of atRA on Bcl-2 upregualtion
(Figure 1F, right panel). This is in line with a previous report
concluding that the atRA/RAR but not atRA/RXR signal
pathway is important for Foxp3 induction [15].
CD4
+ cells primed with atRA and TGF-b displayed
increased suppressive activities in vitro and in vivo
Previous reports have demonstrated that TGF-b-primed CD4
+
cells are hypoproliferative themselves yet are able to suppress
activation and proliferation of other T cells [9,11,16]. As shown in
Figure 2A, when stimulated with anti-CD3 alone, TGF-b-primed
CD4
+ cells had a low proliferative ability. These cells still
produced variable levels of IL-2 (Figure S1E), a possible reason
for their incomplete anergy status. Nonetheless, the addition of
atRA along with TGF-b significantly decreased IL-2 production
and almost completely abolished their proliferation, but this could
be restored through the addition of exogenous IL-2 (Figure 2A).
We next examined their suppressive activity in a standard in vitro
assay. After four days in culture, almost all CD25 expressing cells
were also expressing Foxp3, therefore we could use CD4
+CD25
+-
based magnetic bead isolation to obtain Foxp3+ cells from cells
cultured under the following conditions: TGF-b alone, atRA plus
atRA Promotes iTreg via Histone Modification
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+ cells
were analyzed in standard suppression assay. As shown in
Figure 2B, addition of TGF-b-primed CD4
+CD25
+ cells to
CD25-depleted CD8+ T cells at a ratio of 1:4 significantly
suppressed the CD8
+ T responder cell proliferation in vitro. These
cells similarly suppressed CD4
+ T responder cell proliferation as
well in vitro (not shown). Conversely, addition of CD4
+CD25
+
effector cells (without TGF-b-primed, CD4con) failed to suppress
responder T cell response. Of note, addition of similar doses of
CD4
+CD25
+ cells treated with both atRA and TGF-b resulted in
a greater suppressive activity against the proliferative response of
CD8
+ T cells (Figure 2B) and CD4
+ T cells (Figure 2C)
compared to CD4
+ cells treated with TGF-b alone. We also
observed differential suppressive capacities in vitro using purified
GFP
+ Tregs sorted from TGF-b-primed or atRA/TGF-b-primed
CD4
+ cells using Foxp3
gfp knock-in mice (Figure S2), indicating
the increased suppressive effects of CD4
+ iTregs induced by both
atRA and TGF-b are not simply due to only enriched proportion
of Foxp3
+ cell population in this setting.
Suppressive activity in vitro does not necessarily reflect a
therapeutic effect of Tregs in autoimmune diseases setting in vivo.
To validate and compare the therapeutic effects of both CD4
+ Treg
populations generated as above, we have used a rapid-read lupus
model as previously reported [9]. In this lupus model, the transfer of
parental DBA/2 splenocytes to DBA/2 x C57BL/6 F1 mice caused
polyclonal B cell activation and anti-dsDNA autoantibodies in 1–2
weeks, and proteinuria in 8–12 weeks [9,17]. These pathologic
effects could be significantly decreased by co-transfer of 5610
6
TGF-b-primed CD4
+CD25
+ cells. Furthermore, the levels of IgG,
anti-dsDNA and proteinuria were markedly lower in lupus mice
treated with atRA/TGF-b-primed CD4
+CD25
+ cells than in lupus
mice treated with TGF-b-primed CD4
+CD25
+ cells (Figure 2D). 3
weeks after cell transfer, LN cells in DBA/2 x C57BL/6 F1 mice
resultedinsubstantialnumbersofTh1cell(Figure2E)butfewTh2
and Th17 cells (not shown) compared to F1 mice receiving no cells.
Infusion of TGF-b-primed CD4
+CD25
+ cells significantly sup-
pressed the Th1 frequency in lupus mice whereas treatment with
atRA/TGF-b-primed CD4
+CD25
+ cells resulted in the most
significant suppression against Th1 cell production in lupus
mice (Figure 2E). Accordingly, co-injection of TGF-b-primed
CD4
+CD25
+ cells but not control (CD4con) cells significantly
prolonged the survival of lupus mice in a manner consistent with a
previous report (Figure 2F) [9]. Of note, the protective effect of
atRA/TGF-b-primed CD4
+CD25
+ cells on lupus survival was even
better. While all lupus mice died in 42 weeks following single co-
injection of CD4
+CD25
+ cells treated with TGF-b, more than 60%
of lupus mice still survived at this time point after receiving
CD4
+CD25
+ cells treated with both atRA and TGF-b. Taken
together, these results indicate that addition of atRA to TGF-b
strengthens the quantity and quality of induced Tregs and provide a
better approach to treatment of autoimmune diseases and other
diseases.
The ability of atRA to promote Foxp3
+ regulatory T cell
differentiation is TGF-b signaling dependent
The inability of atRA alone to induce Foxp3 expression by
TCR-stimulated naive CD4
+CD25
2 cells (Figure S1A and C)
indicates that Foxp3 conversion in vitro was exclusively dependent
on exogenous TGF-b [11,13]. This finding is exemplified best
when using TCR-activated naı ¨ve CD4
+ cells isolated from TGF-b
receptor II (TbRII) KO mice. Under these conditions, even a
combination of atRA and TGF-b is unable to induce Foxp3
expression (not shown). Using quantitative PCR methods, we now
showed that TGF-b increases the TbRII expression by CD4
+ T
cells (Figure 3A). atRA alone was unable to increase TbRI (not
shown) and TbRII expression, nor did CD4
+ treated with both
atRA and TGF-b (Figure 3A), indicating the increased binding
ability between TGF-b and TbR in CD4
+ cells does not appear to
contribute to the enhanced effectiveness of atRA to upregulate
TGF-b-induced Foxp3 expression.
We next examined whether atRA affects downstream molecules
in the TGF-b/TbR pathway, subsequently altering TGF-b’s
ability to induce Foxp3 expression. The cellular response to TGF-
b varies by cell type and by the context of the stimulus. In
lymphocytes, TGF-b binds to its cognate receptor complex
composed of type I (ALK5) and type II receptors. TbRII is
required to activate TbRI in the ligand–receptor complex, and
activated TbRI Ser/Thr kinases mainly phosphorylate down-
stream specific Smad2 and Smad3. We first observed that while
TGF-b induces Smad2/3 activation by CD4
+ cells, the addition of
atRA (Figure 3B) slightly increased the level of Smad2/3
phosphorylation 30 min after treatment, with this effect disap-
pearing in 60 min after treatment, suggesting that Smad2/3 early
activation probably plays a role in the enhancement of atRA to
induce Foxp3
+ cell differentiation that is similar with other reports
[18,19].
Nevertheless, recent studies have demonstrated that Smad2 or
Smad3 plays a redundant role in the differentiation of TGF-b-
induced Foxp3
+ cells [11,20], we therefore further studied the role
of atRA in the promotion of iTreg development using Smad2 or
Smad3 KO mice. As shown in Figure 3C, addition of atRA
significantly increased the proportion of Foxp3
+ cells by WT TGF-
b-primed CD4
+ cells, this phenomenon can be similarly observed
in CD4
+ cells isolated from Smad3 KO mice although the
expression levels and intensities of Foxp3 were somewhat lower
compared to WT cells. Because conventional Smad2 KO mice are
early embryonic lethal, we generated lymphocyte-targeted Smad2
conditional knock-out (CKO) mice by crossbreeding floxed Smad2
and hCD2-Cre mice [11]. As with the Smad3 KO mice, addition
of atRA to the TGF-b treated-CD4
+ Smad2 CKO cultures still
resulted in upregulated Foxp3 induction. Moreover, addition of
SIS3, a specific Smad3 inhibitor [11,21], did not alter the levels of
Foxp3 expression in Smad2 CKO CD4
+ cells (Figure 3D),
excluding the possibility that Smad2 and Smad3 compensate for
each other in the promotion of Foxp3
+ cell differentiation. These
Figure 1. atRA sustains Foxp3 expression via apoptosis inhibition. (A) Splenic naı ¨ve CD4
+ cells isolated from Foxp3
gfp mice were stimulated
as described in the Methods section. Percentages of GFP
+ among CD4
+ cells were determined by FACS at the time points indicated. Values were
Mean 6 SEM of three separate experiments. (B). Splenic naı ¨ve CD4
+ cells isolated from Thy1.2 C57BL/6 mice were stimulated with anti-CD3/CD28
coated beads (1:5 ratio) with IL-2 and TGF-b 6 atRA for 4 days and injected to Thy1.2 syngeneic mice. 10, 20, and 30 days later, mice were sacrificed
and Foxp3 expression in the donor cells (Thy1.1
+) in spleen, blood and lymph nodes was determined by FACS. Representative Foxp3 expression data
from LN cells of one mouse per group (n=4). The experiment was repeated with similar results. The percentages of Foxp3
+ cells in specific donor cell
populations (C) and total donor cells (D) in days post injection as indicated are shown. Values were Mean 6 SEM of 8 mice in each time point. (D) The
experiment was conducted as panel A and the expression of Annexin-V
+ among GFP
+ cells were determined by FACS at the time points indicated.
Data is representative of three separate experiments. (F) Total RNA was isolated from different cell groups in panel A and expression of Bcl-2 mRNA
was quantitatively determined by qPCR. Data are Mean 6 SEM of triplicate wells and representative of three different experiments with similar
results. *, p#0.05; **, p#0.01; ***, p#0.001, CD4TGF-b in comparison to CD4atRA+TGF-b.
doi:10.1371/journal.pone.0024590.g001
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+ cell
differentiation via Smad2- or 3-independent signaling pathways.
In addition to Smad signaling, MAPKs including ERK, JNK,
and p38 constitute major non-Smad signaling pathways that play a
supplemental role in mediating the intracellular responses to TGF-
b. As ERK and JNK mainly contribute to iTreg differentiation
[11], we examined whether these non-Smad pathway molecules
are involved in iTreg promotion by atRA. In a protocol as
similarly described for Figure S1, we added different MAPK
inhibitors (or DMSO control) to cultures of CD4
+ T cells
incubated with TGF-b. As shown in Figure 4A, addition of
ERK inhibitors (ERKi) not only completely abolished the
increased Foxp3 expression initiated by atRA, but decreased
Foxp3 expression levels below that induced by TGF-b itself. We
Figure 2. atRA enhances the suppressive activity of TGF-b-iTregs in vitro and in vivo. (A) CD4+ conditioned cells induced as in Fig. 1 were
stimulated with anti-CD3 in the presence of APC for three days and their proliferation were determined by
3H thymidine incorporation. (B, C) CFSE-
labeled effector T cells were cultured at a 1:4 ratio with CD4
+CD25
+ cells isolated from medium treated CD4
+ T cells (+CD4con), TGF-b-CD4
+ cells
(+CD4TGF-b), or atRA/TGF-b-CD4
+ cells (+CD4TGF-b+atRA) or without (Baselines) for 3 days. Representative CFSE plots of the T effector cells are shown as
in B, with the percentages of suppression on T effector cells quantified as in C. (D) A chronic GVHD with a lupus-like syndrome was induced in D2B6F1
mice as described previously. 80610
6 D2 splenocytes were injected into the tail vein (D2 alone). Other groups received this number of D2 cells plus
5610
6 CD4con, CD4TGF-b or CD4TGF-b+atRA. The IgG levels and anti-DNA concentration in mice sera four weeks after cells transfer were determined by
ELISA, and proteinuria levels eight weeks after cell transfer were measured using Albustix reagent strips (Bayer, Elkart, IN). Values are Mean 6 SEM of
6 mice combined with two separated experiments. (E) Similar experiments were conducted as in panel D. Spleen cells from specific groups of mice 3
weeks after cell transfer were harvested and stimulated with PMA (50 ng/ml), Ionomycin (500 ng/ml) for 5 hrs and BFA (5 mg/ml) for 4 hrs. IFN-cf, IL-4
and IL-17 expression on the CD4+ cells was determined by FACS. Data are Mean 6 SEM of three separated experiments. (F) The survival of mice
conducted in panel A was monitored. CD4con vs CD4TGF-b (p,0.01), CD4TGF-b vs CD4TGF-b+atRA (p,0.02) (n=6, each group).
doi:10.1371/journal.pone.0024590.g002
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expression, T cell activation, as well as cell viability (Figure S3),
excluding the possibility that ERKi suppresses Foxp3 induction
because of its global restraint of TCR-stimulation. Addition of
JNKi slightly but not significantly abolished the atRA-regulated
Foxp3 increase. However, the addition of p38i had no effect on
Foxp3 expression. LE540, an RAR antagonist [22], completely
abolished the atRA-regulated Foxp3 increase, providing an ideal
positive experimental control and further suggests that an atRA/
RAR signal is needed for the atRA-regulated Foxp3 increase [15].
Since different subsets of MAPKs may have distinct roles in
atRA-mediated promotion of iTreg differentiation, we next asked
whether addition of atRA can alter the expression of activated
MAPKs in TCR/TGF-b-primed CD4
+ cells. As shown in
Figure 4B and C, naive CD4
+CD25
2 cells appeared to express
activated P42/44 ERK and p38 by 12 hours after stimulating with
anti-CD3/CD28 and IL-2 (med) by Western blotting with
phosphospecific antibodies. In agreement with a previous report
[11], addition of TGF-b alone significantly increased the
activation of ERK but suppressed p38 phosphorylation. Addition
of atRA alone to the cultures significantly decreased ERK and p38
activation. Notably, addition of both atRA and TGF-b signifi-
cantly increased P42/44 ERK early activation and late persistence
(even after 5-day culture) (Figure 4B) although this combination
significantly decreased p38 activation (Figure 4C) and had less
influence on JNK1 activation (Figure 4D). Adding a protein
synthesis inhibitor, cycloheximide (CHX), to the cultures for 6
hours (Figure 4E) and 12 hours (not shown) did not significantly
change ERK activation, suggesting that atRA mainly affects ERK
activation rather than ERK synthesis (Figure 4E). To explain
how atRA sustains the ERK activation (up to five days), we have
demonstrated that addition of Bcl-2 inhibitor can suppress the
Figure 3. atRA promotes Foxp3 differentiation through Smad independent pathway. (A) Naı ¨ve CD4
+ T cells were activated as in Fig. 1.
TbRII expression in different cell groups was analyzed by qPCR. Data are Mean 6 SEM of triplicate wells and representative of four separate
experiments with similar results. (B) The phosphorylation of Smad2/3 was analyzed by Western blot in different cell groups at 30 min and 60 min.
Data are representative of three separate experiments. (C) Naı ¨ve CD4
+ cells isolated from Smad3 KO and wild type mice were TCR stimulated 6 atRA
6 TGF-b for 4 days and Foxp3 expression was analyzed by FACS. Values are Mean 6 SEM of three separate experiments. (D) Naı ¨ve CD4
+ cells were
isolated from Smad CKO mice and SIS3 was added to some cultures. Foxp3 analysis was similarly conducted as panel C. Values are Mean 6 SEM of
three separate experiments.
doi:10.1371/journal.pone.0024590.g003
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shown), suggesting that atRA enhances the cell survival of ERK
activated CD4+ cells. Interestingly, addition of ERK inhibitor also
suppressed the Bcl-2 mRNA up-regulation on CD4+ cells treated
by atRA (Figure 4G), implicating the interaction of atRA, ERK
and Bcl-2 promotes the development and stability of Foxp3+ Treg
cells. Previous studies have reported that atRA inhibits ERK
activation in some cell types and activates ERK in others [23,24].
These results demonstrate that the effect of atRA on the
promotion of TGF-b-induced iTreg differentiation appear to be
mainly through ERK activation and p38 inactivation. ERK and
Bcl-2 interaction may promote the effect of atRA on iTreg
promotion and maintenance.
atRA promotes iTreg development and maintenance
through epigenetic modulation of histones rather than
through DNA methylation of the Foxp3 gene locus
Given the critical role of atRA in iTreg promotion and
maintenance, we sought to explore possible mechanisms for
regulation at epigenetic levels. Others have reported that DNA
methylation in Foxp3 gene promoter and CpG sites in the +4,201
to +4,500 intronic CpG island in conserved non-coding DNA
sequence 3 (CNS3) at the Foxp3 gene locus affects Foxp3
expression and maintenance by Tregs [25,26]. We analyzed the
DNA methylation in CpG islands in CNS3 of the Foxp3 locus
using a previously described method [27]. Potential CpG
methylation sites in CNS3 are outlined in Figure 5A. Naı ¨ve
CD4
+CD25
2 cells were stimulated with TCR + IL-2 6 atRA
and/or TGF-b for 4 days. Of the eight independent clones we
noticed that only 1–3 demethylation sites scattered in these ten
CpG sites, which may reflect a fluctuation. Each of the different
treatments caused a slight shift in the methylation patterns, but
overall they were not significantly different. Therefore, atRA-
promoted iTreg development and stability does not appear to be
related to the alteration of methylation status of CpG sites in
CNS3 in the Foxp3 locus.
In addition to DNA CpG site methylation in Foxp3 locus, we
also asked whether atRA affects post-translational modification of
histones. As the transcribed regions of active genes are usually
associated with modification at histone H3K4 [28], we therefore
first examined methylation at this histone in the promoter as well
as in the CNS elements at the Foxp3 locus. When CD4+ T cells
were cultured with atRA or TGF-b, chromatin immunoprecipi-
tations (ChIPs) revealed a significant enrichment for H3K4me3,
one of characteristic epigenetic marks of actively transcribed genes
for chromatin. The peak accumulation of H3K4me3 was observed
on the CNS2 in CD4+ cells treated with atRA alone and on the
promoter in the CD4+ cells treated with both atRA and TGF-b
(Figure 5B), suggesting that while TGF-b promotes histone
H3K4me4 methylation level at promoter region of Foxp3 and
facilitates iTreg generation, atRA can dramatically enhance
histone methylation level at CNS2 of Foxp3 and at least benefit
iTreg maintenance. Previous work had documented that CNS3
facilitates Foxp3 induction whereas CNS2 favors the Foxp3
maintenance [29]. We examined histone H3k4me1, H3K4me2
and H3K9 methylation levels in the promoter and CNS1-3 region
of Foxp3 locus in CD4+ cells and their enrichments did not
correlate with atRA treatment in CD4+ cells (not shown).
In addition to methylation, lysine acetylation is well known for
the epigenetic regulation of gene transcription in immune system
[28]. Previous work has demonstrated that atRA increases histone
acetylation of the Foxp3 promoter regions in natural Tregs [12].
To address whether atRA also affects histone acetylation of the
Foxp3 promoter regions in iTregs, we measured the histone
acetylation in the proximal 59 promoter using chromatin immuno-
precipitation (ChIP) in conjugation with qPCR. We examined the
H3 N-terminal acetylation around the transcription start site (TSS)
of Foxp3 gene. As shown in Figure 5C, TGF-b alone slightly
increased the H3 acetylation in TSS, while atRA alone had no
impact. However, atRA in concert with TGF-b significantly
boosted the acetylation in the TSS. Phosphorylation at ser-5 and
ser-7 of RNA polymerase II is a marker for active transcription
[30]. We found that TGF-b but not atRA increased recruitment of
phopshorylated RNA pol II in the TSS. Additionally, atRA
marginally stimulated additional recruitment of RNA pol II in the
promoter. Together, these results suggest that atRA promotes
Foxp3 induction and maintenance through modulating epigenetic
settings either in a locus-specific manner or globally on chromatin.
We further evaulated the functional outcome of epigenetic
modulation regulated by atRA at the Foxp3 locus. To address this,
we examined the extent to which atRA stimulation can modify the
level of Foxp3 that is bound to chromatin. As shown in
Figure 5D, we noted significantly greater amounts of Foxp3 in
the nuclear fraction (nucleoplasm) 3 days after TCR stimulation
with atRA plus TGF-b. Chromatin-associated Foxp3 was found to
significantly increase over time in cultures containing both atRA
and TGF-b relative to either alone (Figure 5D). These results
indicate that atRA plus TGF-b stimulation increases the amount
of Foxp3 associated with chromatin in CD4
+ T cells. Increased
levels of Foxp3 in the chromatin fraction may facilitate its
functional activity during an immune response.
Discussion
Emerging evidence indicates that atRA promotes the differen-
tiation of TGF-b-induced Foxp3
+ cells [6]. We have confirmed
this finding and also demonstrated that CD4
+ cells induced by a
combination of atRA and TGF-b displayed superior suppressive
function in vitro and adoptive transfer of these cells resulted in
much better suppressive effects on lupus disease development in
animal model compared to CD4
+ cells treated with TGF-b alone,
implicating that a combination of atRA and TGF-b provides an
ideal protocol for the preparation of iTreg population and their
use in the clinical cell therapy in treating autoimmune disease and
organ transplantation settings.
Figure 4. atRA promotes Foxp3 expression through ERK activation and maintenance. (A) Naı ¨ve CD4 T cells were stimulated as in Fig. 1.
The different MAPKs inhibitors, DMSO or LE540 were added to some cultures. Values indicate Foxp3 expression and are Mean 6 SEM of four separate
experiments. (B–D) These cells were stimulated as in panel A for 12 and 120 hrs and ERK, p38 and JNK1 activation was examined by Western blot. The
data shown are representative of three independent experiments. The relative density of activated ERK, p-38 and JNK1 to total ERK, p-38 and JNK1
was quantified by Quantity One software and values are Mean 6 SEM of three separate experiments. (E) Naı ¨ve CD4
+ cells were stimulated as in panel
B for 6–12 hrs. In some cultures, cycloheximide (20 mg/ml, Sigma, C1988) or control DMSO were added to cultures for 6 and 12 hrs. Values are Mean
6 SEM of relative density of ERK1/2 activation for three separate experiments with 6 hrs stimulation. (F) Experiments were similarly conducted as in
panel E and ERKi and ABT263 (Bcl-2 inhibitor, 5 mM, Selleck) were added to cultures for 12 hrs (F) to 5 days (not shown) and ERK1/2 activation was
similarly determined as panel E. Values are Mean 6 SEM of three separate experiments. *p,0.05, **P,0.01, ***p,0.001 (student t test).
doi:10.1371/journal.pone.0024590.g004
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PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e24590The addition of atRA not only increased the differentiation of
Foxp3
+ cells, but also maintained Foxp3 expression by TGF-b-
primed CD4
+ cells. This finding could be explained by increased
induction and/or decreased apoptosis. It has been well docu-
mented that activated lymphocytes are prone to activation-
induced cell apoptosis. Although TGF-b prevents activated
lymphocytes from apoptosis, our data demonstrate that a
combination of atRA and TGF-b markedly increased the
expression of anti-apoptotic protein such as Bcl-2 in CD4
+ cells,
and that these increases are accompanied with decreased numbers
of Annexin-V
+GFP
+ (apoptotic Foxp3
+) cells, an indication that
these cells from apoptosis, eventually leading to the maintenance
of Foxp3 expression. atRA-mediated upregulation of Bcl-2 seems
to be dependent upon the RAR- rather than RXR-signal pathway,
and this parallels with the role of atRA/RAR signal pathway in
the Foxp3 induction [15]. Another possibility is that atRA can
expand the Foxp3
+ cells that had been induced by TGF-b.I n
addition to the direct effect of atRA on promoting iTreg
differentiation, atRA also suppresses the expansion of T effector
cells and Th17 cell differentiation induced by a combination of IL-
6 and TGF-b [6,8]. Cytokines produced by effector T cells will
diminish the Treg phenotypes and increase the Treg plasticity
[19], although others have reported that atRA can interfere
directly with decrease in Treg conversion caused by costimulation
and that it can enhance Treg conversion from naive T cells
independently of secreted cytokines [31]. Recently, the role of
atRA in maintenance of expanded nTregs has also been
documented [19].
The addition of atRA to TGF-b endows CD4
+ cells with an
almost complete anergic status (Figure 2A). This effect could be
explained by their decreased IL-2 production and/or an increase
in IL-10 production. Our data revealed that CD4
+ cells treated
with TGF-b plus atRA exhibited a lower IL-2 production, a
finding which might have contributed to their anergic phenotype.
Although IL-10 production by CD4
+ cells treated with atRA and
TGF-b was not markedly increased, its involvement in the role of
atRA in iTreg cell development is still unclear. Another group
recently reported that the addition of atRA to TGF-b suppresses
the production of IL-10 [32]. Our previous work has demonstrat-
ed that TGF-b induces iTreg development through IL-10-
independent pathway [33].
One of the interesting findings in the current study is that
atRA/TGF-b-induced CD4+ regulatory T cells exhibit an
enhanced suppressive T cell response in vitro and ameliorated
lupus syndromes in a chronic GVHD animal model. These
findings can not simply be explained by enhanced Foxp3
expression on CD4
+ cells treated with both atRA and TGF-b
compared with TGF-b alone since use of purified individual
Foxp3
+ cells from both groups of cells still displays the similarly
functional differences. The remarkable suppressive function of
atRA/TGF-b-induced CD4
+ regulatory T cells in lupus mice may
be related to the alteration of the phenotypes, stability and
functionality of these cells in vivo. Our findings have demonstrated
that iTregs induced with atRA/ TGF-b survived longer and
mainained higher Foxp3 expression compared to iTregs induced
with TGF-b alone in vivo.
We have been focusing on an investigation of the molecular
mechanism(s) by which atRA promotes the iTreg development
and maintenance. An interrupted TbR signaling pathway would
abolish the effect of atRA on the increase of Foxp3
+ cell
production, and this suggests that atRA should affect TGF-b
signaling rather than TGF-b affects atRA signaling. Previous
studies have demonstrated quite clearly that the TGF-b signaling
pathway is crucial for the induction of Foxp3
+ cells [11].
Conversely, the TGF-b-mediated induction is RA receptor a
(RAR-a) independent although this receptor is crucial for the
effect of atRA on T cell response [12]. In addition, atRA alone
without TGF-b is unable to induce Foxp3
+ iTregs (Figure S1A
and C).
The two pathways that can regulate TGF-b signaling include
the Smad- and non-Smad pathways. Unlike TGF-b, which can
upregulate TbRI and II expression by CD4
+ cells, atRA did not
increase TbRI and II expression by CD4
+ cells (Figure 3A),
implicating that atRA possibly regulates TGF-b signaling pathway
through downstream molecules.
Smad2 and Smad3 are two main targets of activated TbRI and
II. Accumulating evidence has revealed that Smad3 is essential for
the suppressive effect of TGF-b on IL-2 production, T cell
proliferation as well as Th2 type cytokine productions and Th2
type disease in the skin [11]. Although the role of Smad2 or
Smad3 in the induction of iTregs is a non-essential one [11,20], it
is unclear whether Smad2/3 is involved in the enhanced effects of
atRA on Foxp3
+ cell differentiation induced by TGF-b. Our data
showed that the addition of atRA to TGF-b slightly increased
Smad2/3 activation in the 30 min time point but this effect rapidly
disappeared by 60 min, implicating that atRA possibly enhances
the induction of Foxp3
+ cells through the early initiation of
Smad2/3 activation. One group has also demonstrated that atRA
increases the quantity of Foxp3
+ Tregs by enhancing TGF-b-
driven Smad3 signaling while another group recently demonstrat-
ed that atRA increases histone acetylation in the Smad3 binding
sites and binding ability of activated Smad3 [7,34]. We found that
even when using either Smad3 KO or Smad2 CKO mice,
addition of atRA to TGF-b treatment still increased Foxp3
+ cell
induction from TCR-activated CD4
+ cells although the levels and
mean fluorescence intensity (MFI) of Foxp3 were slightly lower
than that in WT mice. Another laboratory group has made a
similar observation using Smad3 KO mice as well [31]. However,
Xu et al recently observed that Smad3 is essential for the atRA
promotion in Treg differentiation [34]. To explain the difference
in the role of Smad3, we would suggest that differences in Treg
generation protocols between the two laboratories might contrib-
ute to these disparate findings. While Xu et al used plate-bound
TCR stimulation, our work has used anti-CD3/CD28 coated
Figure 5. atRA and TGF-b affect histone modification not DNA methylation in the Foxp3 gene locus, and also increase the DNA
binding ability of Foxp3 protein. (A) Naive CD4+ cells were stimulated as Fig. 1. The DNA methylation status in CNS3 of the Foxp3 gene locus
was determined by bisulfite sequencing analysis. Each line represents one DNA strand; open circle, unmethylated CpGs; filled circle, methylated CpGs.
(B) Naı ¨ve CD4+ cells were stimulated as in Panel A. ChIP-qPCR detection of H3K4me3 enrichment at promoter, CNS2 and CNS3 of Foxp3. Data are
representative of two similar experiments. (C) A ChIP-qPCR analysis was performed to determine histone acetylation in the Foxp3 promoter. The b-
actin gene was included as an internal control. Antibodies for N-terminal histone H3 and ser-5-phopho-RNA pol II were used for immunoprecipitation.
The DNA fragments bound to the proteins were determined by qPCR analysis. Results showed are Mean 6 SEM of four separate experiments.
**p,0.01 (student t test). (D) Cellular compartments were fractionated into cytoplasmic, nuclear, and chromatin fractions. Equal amounts of proteins
were separated by 8% SDS/PAGE, and then transferred to nitrocellulose membrane. Chromatin fractions were immunoblotted successively with
antibodies against Foxp3 and b-actin. Relative density of Foxp3 expression was quantified with Quantity One software and values are Mean 6 SEM of
three separate experiments. **p,0.01 (student t test).
doi:10.1371/journal.pone.0024590.g005
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induced Treg development needs to be further explored with
different protocols and other Smad3 knock-out strains.
In the current study, we demonstrate that atRA promotes
iTregs differentiation through the MAPK pathway. We observed
that the addition of ERK inhibitors completely abolished the
enhanced effects of atRA on the promotion of TGF-b-induced
Foxp3
+ cells. Using cell activation and proliferation experiments,
we showed that ERK inhibitors specifically suppressed the
increase of Foxp3
+ iTreg populations rather than nonspecific
suppression of global T cell activation. Consistent with this result,
we also observed that the addition of atRA to TGF-b significantly
increased ERK activation without enhancing JNK. Conversely,
atRA actually suppressed p38 activation. Since p38 activation is
associated with T effector cell development and disease patho-
genesis [35], atRA may have dual roles in both promoting Treg
induction while suppressing T effector cells. The identification of
these signaling pathways sheds light on the mechanisms by which
atRA promotes the development of the induced Treg subset and
will allow for the development of therapeutics that can target
specific TGF-b responses in autoimmune and inflammatory
diseases.
Our study has also illuminated an intrinsic relationship between
Bcl-2 upregulation and ERK activation. ERK activation plays an
important role in iTreg induction and promotion of atRA-
mediated iTreg differentiation and maintenance. We found that
blockade of ERK activation not only suppressed Foxp3 genera-
tion, but Bcl-2 upregulation as well. In addition, blockade of Bcl-2
decreases ERK activation, indicating Bcl-2 regulation and
interaction of Bcl-2 and ERK may contribute to iTreg
maintenance. Future study is needed to determine whether ERK
can directly bind Bcl-2 in iTreg cells.
One of the most interesting findings in the current study is that
atRA not only promotes iTreg generation and maintenance, but
may also alter the binding ability of Foxp3 protein on chromatin.
In mammals, epigenetic regulation is mediated by changes in
chromatin structure, resulting from either histone modification or
DNA methylation [28]. Moreover, we observed that addition of
atRA did not alter DNA methylation status in CNS3 sites of the
Foxp3 locus in TGF-b-primed CD4
+ cells. Although others have
claimed that incomplete CpG demethylation in Tregs leads to the
loss of Foxp3 expression and suppressive activity [25], the addition
of atRA enhances and sustains Foxp3 expression in iTregs, and
these cells display an exceptionally strong suppressive activity
(Figure 2B–F), indicating that CpG DNA demethylation of the
Foxp3 locus may not be a crucial factor in Treg stability and
functionality.
Histone modification represents another possible mechanism in
the regulation of gene expression and chromatin structure [36].
For example, histones can be methylated on lysine and arginine
(R) residues, acetylated on lysine (K) residues, phosphorylated on
serine and threonine (S/T) residues or ubiquitinated/SUMOy-
lated on lysine residues [37]. Histone methylation is more complex
and can be associated with either gene activation or gene
repression depending on the methylated residue and the degree
of methylation, since lysine residues can be mono-, di- or tri-
methylated (me1, me2 or me3). In general, the H3K4me3 level
indicates gene activation while the H3k27me3 level indicates a
repressed gene activity [28]. Our study revealed that atRA or
TGF-b treatment can significantly increase the methylation in
histone H3K4 in the Foxp3 gene promoter and both atRA and
TGF-b treatment upregulated methylation of H3K4 in CNS2 at
the Foxp3 locus, indicating that atRA and TGF-b have a
synergistic role in the maintenance of Foxp3 but a separate role
in Foxp3 induction. Although in an in vitro culture, we failed to
observe that atRA alone induced Foxp3 expression, others have
reported that atRA treatment induced Treg cell-dependent
immune tolerance by suppressing both CD4(+) and CD8(+) Teff
cells while promoting Treg cell induction and expansion in vivo
[38]. Future study is needed to determine if atRA also affects the
level of histone H3K27me3 modification at the CNS1-3 sites of
the Foxp3 locus. Moreover, whether atRA can affect Foxp3
protein acetylation needs to be further addressed since acetylation-
mediated Foxp3 protein displayed markedly increased stabilization
and functionality [39].
An initial step in the relaxation of chromatin structure is the
enzymatic addition of acetyl groups to the positively charged tails
of histone H3 and H4 by histone acetyltransferases. Histone
acetylation often accompanies gene transcription [40], which is
required for the appropriate tissue-specific and context-dependent
induction of many genes, and is opposed by the activity of histone
deacetylases [41]. We hypothesized that the histone acetylation
status of the Foxp3 promoter is responsible for the enhanced
effects of atRA on iTreg promotion. Using a ChIP assay, we
observed that TGF-b alone can indeed promote Foxp3 acetyla-
tion, a finding that is agreement with a previous report [42]. Of
note, the histone (H3) acetylation status in iTregs induced by
TGF-b and atRA was significantly increased, suggesting that
histone/protein deacetylases (HDACs) regulate chromatin remod-
eling and Foxp3 gene expression and function. It is possible that
atRA also affects the histone acetylation in the enhancer region of
the Foxp3 gene [34]. Although portions of the total pool of Foxp3
can exist in diverse nuclear sites such as within the nucleoplasm,
active and acetylated Foxp3 is preferentially, but not exclusively,
bound to chromatin. In fact, histone deactylase inhibitors affect
the chromatin binding pattern of Foxp3 [43]. These data suggest
that the effect of atRA on Foxp3 mediated regulation of its target
gene may be differential and site-dependent, which could explain
the differential effect of atRA treatment on the differential
induction and function of Foxp3+ Treg cells (Figure 2).
In summary, we found that atRA markedly promotes the
phenotypic and functional development and maintenance of TGF-
b-induced iTregs. Adoptive transfer of these cells to lupus mice
highlights their efficient suppressive activity in controlling disease
development. We explored the mechanisms involved in the iTreg
promotion by atRA, finding that atRA synergizes with TGF-b
signaling to induce iTregs mainly via ERK1/2 pathways.
Moreover, we observed that atRA significantly increases histone
modification including methylation and acetylation but does not
affect the DNA demethylation status of CNS3 in the Foxp3 gene
locus. We conclude that alterations in the induction and
maintenance of Foxp3 gene expression and the conformational
changes which promotes its binding on chromatin might both
account for increased suppressive activity and stability of iTregs.
Materials and Methods
Mice
C57BL/6 mice were purchased from The Jackson Laboratory.
Smad2
fx/fx and Smad3 KO mice were provided by Dr. Xiao-Fan
Wang at Duke University and Dr. Michael Weinstein at Ohio
State University. hCD2-Cre mice were provided by Dr. Dimitris
Kioussis at National Institute for Medical Research. Foxp3 GFP
knock-in mice were a gift from Dr. Talil Chatilla (UCLA).
Lymphocyte-specific Smad2 conditional knockout (CKO) mice
were generated by crossing Smad2
fx/fx with Smad2
fx/fx/hCD2-Cre
mice. Mice with genotype of Smad2
fx/fx were used as a normal
control. All animals were treated according to National Institutes
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approval of the University of Southern California Committee for
the Use and Care of Animals (IACUC #11481).
Cell differentiation and functional assay
Naı ¨ve splenic CD4
+CD25
2CD44
low cells were stimulated with
anti-CD3/CD28 beads (Invitrogen, Carlsbad, CA) at a bead/T
cell ratio of 1:5 + IL-2 (20 U/ml, R&D system) 6 TGF-b (2 ng/
ml, R&D system) for the generation of Foxp3
+ Tregs for the
numbers of days indicated in the different figure legends. 3 mM
SIS3 (Smad3 inhibitor, Calbiochem) was added to cultures one
hour before TCR stimulation. An equivalent volume of DMSO
was added to cultures as a control. To assess suppressive activities,
CD4
+CD25
+ cells were isolated using MACS beads from CD4
+
conditioned cells after 4-day culture. T cells labeled with CFSE
(Invitrogen, Carlsbad, CA) were stimulated with soluble anti-CD3
(0.025 mg/ml) with irradiated non-T cells as APC (1:1). The
CD4
+CD25
+ cell population generated from different groups of
mice were added at a ratio of 1:4 and suppression of cycling
CFSE-labeled T cells was assessed as described previously [44]. In
other experiments, a [
3H] thymidine incorporation assay was also
used to evaluate the suppressive activity of iTregs [33]. AIM-V
serum-free medium (Invitrogen Life Technologies) supplemented
with 100 U/ml penicillin, 100 mg/ml streptomycin, and 10 mM
HEPES (all obtained from Invitrogen Life Technologies) was used
for the generation of CD4
+ iTreg or control cells. RPMI 1640
medium supplemented as above with the addition of 10% heat-
inactivated FCS (HyClone Laboratories) was used for all other
cultures.
Flow cytometry
Anti-TGF-b RII, CD4, CD25, CCR-9,a4b7,CTLA-4, CD28,
CD103, CD126, CD127, CD130 and Foxp3 fix/perm buffer set
were purchased from Biolegend (San Diego, CA). Anti-TGF-b was
a gift from eBioscience. For intracellular/intranuclear staining,
cells were first stained with surface antibodies, then were fixed/
permeabilized in cytofix/permeabization solution (Biolegend) and
stained with anti-CTLA-4 or anti-Foxp3.
Real-Time PCR
Total RNA was extracted with the RNeasy mini kit (Qiagen,
Valencia, CA). cDNA was generated using a Omniscript RT kit
(Qiagen, Valencia, CA). Foxp3 mRNA expression was quantified
with ABsolute SYBR Green ROX mix (Thermo, Waltham, MA).
The samples were run in triplicate and the relative expression of
Foxp3 was determined by normalizing the expression of each
target to hypoxanthine guanine phosphoribosyl transferase
(HPRT). Primer sequences were as follows: HPRT 59-TGA
AGA GCT ACT GTA ATG ATC AGT CAA C-39 and 59-AGC
AAG CTT GCA ACC TTA ACC A-39; Bcl-2, 59-CCT GGC
TGT CTC TGA AGA CC-39 and 59-CTC ACT TGT GGC
CCA GGT AT-39.T bRII, 59-GGC TCT GGT ACT CTG GGA
AA-39 and 59-AAT GGG GGC TCG TAA TCC T-39.
Western blot analysis
Western blot was performed as previously described [44]. Biefly,
cells were lysed in buffer containing 25 mM Tris-HCl, 1%
deoxycholate, 0.35 M NaCl, phosphatase inhibitor solution
(Cayman Chemical), and 1% Triton X-100 (Fischer Scientific).
Protein quantity was assayed by bicinchoninic acid (Pierce,
Chemical Co.) and 20 mg of protein was loaded per well on a
15% Tris-HCl gel (Bio-Rad). The contents of the gel were
transferred in a Trans-Blot semi-dry transfer cell (Bio-Rad) onto
nitrocellulose membranes (Amersham Biosciences). The mem-
branes were incubated with different Abs. Ab-bound proteins were
detected using an ECL Western blotting analysis system
(Amersham Biosciences), and the membranes were exposed to
Kodak Biomax XL x-ray film.
Nuclear and DNA preparation
Nuclear extracts were prepared according to the methods of Li
et al with some modification [45]. Genomic DNA was prepared
using the Qiagen Blood & Cell Culture DNA Kit or the Qiagen
DNeasy Blood & Tissue Kit when working with smaller cell
numbers. DNA concentration was determined with the NanoDrop
spectrophotometer and quality was assessed by agarose gel
electrophoresis.
Cell lysis, immunoprecipitation, and immunoblotting
Cell lysates were obtained by cell lysis in RIPA buffer (50 mM
TrisNHCl, pH 7.4, 0.5% Nonidet P-40, 0.25% Na-deoxycholate,
150 mM NaCl, 1 mM EDTA, with 1 mM PMSF, 1 mg/ml each
of Aprotinin, leupeptin and pepstatin, 1 mM Na3VO4, and 1 mM
NaF), followed by immunoprecipitation with the indicated
antibodies, SDS/PAGE, and analyzed by Western blotting with
standard procedures. ECL or ECLplus Western blotting detection
reagents were used (Amersham Pharmacia Biosciences).
Foxp3 methylation analysis
Foxp3 methylation analysis was conducted with a method as
previously reported [26]. In brief, genomic DNA was sonicated to
a mean fragment size of 350–400 bp. Four micrograms of each
sample was incubated with 200 mL of Protein A–Sepharose 4 Fast
Flow beads (GE Healthcare) coated with 80 mg of purified MBD-
Fc protein in 2 mL of Ultrafree-MC centrifugal filter devices
(Amicon/Millipore) for 3 h at 4uC in buffer containing 300 mM
NaCl. Beads were centrifuged to recover unbound DNA
fragments (300 mM fraction) and subsequently washed with
buffers containing increasing NaCl concentrations (350, 400,
450, and 1000 mM). All fractions were desalted using the
MinElute PCR purification kit (Qiagen). The distribution of
CpG methylation densities of individual MCIp fractions was
controlled by qPCR using primers covering the imprinted SNRPN
and a genomic region lacking CpGs (empty 6.2). Fractions
containing unmethylated DNA (300,400 mM) or methylated
DNA ($450 mM) were pooled before subsequent labeling.
ChIP (chromatin immuno-precipitation)
ChIP assays were carried out with 5,10 million cells with or
without stimulation by using EZ-ChIP (cat. 17–371, Upstate
Biotechnology) according to the manufacturer’s instructions. After
sonication on ice, the chromatin solution was centrifuged for
10 min at 6,0006 g. mIgG (Upstate Biotechnology), anti-acetyl
histone H3 (Upstate Biotechnology), or anti-mono-methyl-histone-
K4 H3 (Cell signaling), or anti-di or tri-methyl-histone-K4 H3
(Abcam), or anti-Foxp3 (e-Bioscience) were used for immunopre-
cipitation of the supernatant. ChIP analysis was carried out
according to the manufacturer’s protocol (Upstate/Millipore,
Billerica, Massachusetts, United States). Cells (1,5610
6) were
fixed with 1% formaldehyde, and chromatin was fragmented by
ultrasound. For all ChIP samples, sheared chromatin was
precleared by incubation with ProteinA-agarose/salmon sperm
DNA (Upstate/Millipore). Subsequently, chromatin was immu-
noprecipitated by overnight incubation at 4uC with 4-mg
antibodies (rabbit isotype, #2027, Santa Cruz Biotechnology,
Santa Cruz, California, United States; anti–acetyl-histone H3,
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Upstate/Millipore; anti–tri- or di-methyl-K4-histone H3, ab303938,
abcam; and anti-mono-methyl-K4-histone H3, #5326, cell signaling.)
followed by incubation with Protein A-agarose/salmon sperm DNA
for 1 h. Precipitates were defixed and DNA was purified by using the
NucleoSpin Extract II kit (Macherey-Nagel, Du ¨ren, Germany). The
amount of immunoprecipitated DNA was quantified by real-time PCR
with LightCycler (Roche Applied Science, Basel, Switzerland) using
SYBR Green and the following Foxp3 primer pair 59-GAC TCA AGG
GGG TCT CA-39;5 9-TTG GGC TTC ATC GGC AA-39.F o r
histone methylation level assay at Foxp3 regions, following primers were
used: Promoter forward primer: 59-CTGAGGTTTGGAGCA-
GAAGGA-39, reverse primer: 59-TCTGAAGCCTGCCATGTGAA
-39;C N S 2f o r w a r dp r i m e r :5 9-GTTGCCGATGAA GCCCAAT -39;
reverse 59- ATCTGGGCCCTGTTGTCACA-39;C N S 3f o r w a r d
primer: 59- AATGAATG AGACACAGAACTATTAAGATGA -39;
reverse primer: 59-CAGACGGTGCCACCATGAC -39.
Statistical analysis
Results were calculated by using GraphPad Prism 4.0 software
(GraphPad Spftware, San Diego, CA) are presented as mean 6
SEM. Differences in Kaplan-Meier survival curves were analyzed
by the log-rank test. Student t test was used to assess statistical
significance between two groups, and one-way ANOVA and/or
non-parametric tests were used to assess statistical significance
among multi-groups. Protein quantification in Western Blot was
analyzed by Quantity One software (Bio-Rad, Hercules, CA). P
value,0.05 is considered as statistically significant difference.
This work was presented in the plenary session of the 2009
annual conference of American College of Rheumatology in
Philadelphia.
Supporting Information
Figure S1 atRA enhances Foxp3 expression induced by
TGF-b in CD4
+ T cells. Naı ¨ve CD4
+ T cells isolated from
C57BL/6 (A) or Foxp3
gfp (B) spleen using magnetic beads were
stimulated by anti-CD3/CD28 beads 6 TGF-b 6 atRA for 4
days. Foxp3 expression was analyzed by flow cytometry. Values
are Mean 6 SEM (A) and representative (B) of five separate
experiments. (C) Foxp3 expression by these cells was analyzed by
Western Blot (atRA, 0.2 mM). Results are representative of three
separate experiments. (D) Absolute numbers of Foxp3
+ (GFP
+)
cells were presented in different time points of these cells. Mean 6
SEM of four independent experiments is shown. (E) Cell
phenotypes were analyzed by two different cell subsets. Data is
representative of four separate experiments.
(TIF)
Figure S2 Purified CD4
+Foxp3
+ cells induced by atRA
and TGF-b resulted in increased suppressive activity in
vitro. Naı ¨ve CD4
+ T cells isolated from Foxp3
gfp spleen using
magnetic beads were stimulated by anti-CD3/CD28 beads 6
TGF-b 6 atRA for 4 days. Foxp3 (GFP) expression by CD4
+ cells
was analyzed and sorted by flow cytometry after cultures. Freshly
sorted GFP
+ (nTregs) and GFP
2 (control) cells in Foxp3
gfp mice
were served as positive or negative controls. These cells were
added to anti-CD3-stumlated GFP
2 T responder cells in the
presence of APC and their suppressive activity was analyzed by
thymidine [H
3] incorporation assay as previously described [16].
Mean 6 SEM of triplicate experimental data in each group is
shown. Data is representative of three separate experiments.
(TIF)
Figure S3 MAPK inhibitors did not affect the cell
viability. Naı ¨ve CD4 T cells were stimulated with anti-CD3/
CD28 coated beads 6 TGF-b 6 atRA for 4 days. The different
MAPKs inhibitors, DMSO or LE540 were added to some
cultures. Total viable cell numbers were counted in each well.
Values indicate viable cell counts and are Mean 6 SEM of four
separate experiments.
(TIF)
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